Effect of one‐week oral or inhaled salbutamol treatment with washout on repeated sprint performance in trained subjects. Issue 2 (24th November 2020)

• Record Type: Journal Article
• Authors: Eibye, Kasper; Jacobson, Glenn A.; Bengtsen, Kasper; Jessen, Søren; Backer, Vibeke; Bangsbo, Jens; Hostrup, Morten
• Is Part Of: Translational sports medicine. Volume 4:Issue 2(2021)
• Page Start: 241
• Page End: 249
• Publication Date: 2020-11-24
• Subjects: asthma -- beta2‐agonist -- doping -- exercise‐induced bronchoconstriction -- performance -- salbutamol -- wingate; Sports medicine -- Periodicals; Sports injuries -- Periodicals; 617.1027
• DOI: 10.1002/tsm2.210
• Languages: English
• ISSNs: 2573-8488

Abstract

Abstract : Background: Acute and chronic supratherapeutic treatment with the commonly used beta2‐agonist salbutamol has the potential to enhance sprint performance and muscle strength. However, little is known about the performance effects of short‐term daily permitted inhaled treatment vs oral prohibited treatment in accordance with the 2020 Prohibited List issued by the World Anti‐Doping Agency (WADA). Methods: Herein, we investigated the effect of twice‐daily treatment with 400 μg inhaled or 4 mg oral salbutamol for 1 week on repeated sprint performance in 19 healthy well‐trained men and women utilizing a randomized open‐label crossover design. Before and after each treatment period, and a 12‐16 hours washout to avoid an acute effect of salbutamol, subjects performed a repeated sprint test (3 × 30‐second Wingate). Results: Neither oral nor inhaled salbutamol enhanced peak power (oral; 3.0 W; 95% CI −6.8 to 12.8 W; and inhaled; −3.8 W; 95% CI −14.3 to 6.8 W) or mean power (oral; −2.1 W; 95% CI −4.7 to 8.9 W and inhaled; −1.6 W; 95% CI −5.6 to 8.9 W) during the repeated sprint test irrespective of gender. Conclusions: These findings indicate that 1 week is insufficient for salbutamol to induce any relevant effect on repeated sprint performance in trained individuals.